ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1203

Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series
Abstract Number: 1204

Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.
Abstract Number: 1205

Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Abstract Number: 1206

Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Abstract Number: 1207

Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Abstract Number: 1208

Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Abstract Number: 1209

Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Abstract Number: 1210

Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
Abstract Number: 1211

Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Abstract Number: 1212

Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Abstract Number: 1213

Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
Abstract Number: 1214

Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis
Abstract Number: 1215

Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort
Abstract Number: 1216

Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies
Abstract Number: 1217

Validation and clincial use of anti-MDA5 test – LIA versus ELISA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].